Organogenesis (ORGO) Stock Price, News & Analysis

Company Overview

Organogenesis Inc. operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures. These products are supported by clinical data demonstrating efficacy in accelerating wound closure and improving patient outcomes in both inpatient and outpatient settings.

Headquartered in Canton, Massachusetts, Organogenesis maintains manufacturing and distribution capabilities in North America with a network of clinical and commercial operations aimed at expanding access to advanced wound care and regenerative therapies. The company continues to invest in research and development to broaden its product pipeline and pursue collaborations that enhance its position in the global regenerative medicine market.

Key Stats

• Today's Range: $1.63 to $1.73
• 50-Day Range: $1.63 to $2.68
• 52-Week Range: $1.54 to $7.08
• Volume: 665,508 shs
• Average Volume: 1.04 million shs
• Market Capitalization: $220.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.33
• Consensus Rating: Reduce

Organogenesis Stock Analysis - MarketRank™

Organogenesis scored higher than 28% of companies evaluated by MarketBeat, and ranked 766th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Organogenesis has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Organogenesis has a consensus price target of $4.33, representing about 153.1% upside from its current price of $1.71.

Amount of Analyst Coverage

Organogenesis has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Organogenesis is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organogenesis is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Organogenesis has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.62% of the float of Organogenesis has been sold short.

Short Interest Ratio / Days to Cover

Organogenesis has a short interest ratio ("days to cover") of 11.74, which indicates bearish sentiment.

Change versus previous month

Short interest in Organogenesis has recently increased by 6.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organogenesis does not currently pay a dividend.

Dividend Growth

Organogenesis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Organogenesis has a news sentiment score of -0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Organogenesis this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for ORGO on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Organogenesis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organogenesis insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.80% of the stock of Organogenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

49.57% of the stock of Organogenesis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/04/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ORGO
• CIK: 1661181
• Web: organogenesis.com
• Phone: (781) 575-0775
• Fax: N/A
• Employees: 950
• Year Founded: 1985

Price Target and Rating

• Average Price Target for Organogenesis: $4.33
• High Price Target: $8.00
• Low Price Target: $2.00
• Potential Upside/Downside: +153.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $37.03 million
• Net Margins: -19.94%
• Pretax Margin: -7.60%
• Return on Equity: -23.89%
• Return on Assets: -11.13%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 3.52
• Quick Ratio: 3.00

Sales & Book Value

• Annual Sales: $564.17 million
• Price / Sales: 0.39
• Cash Flow: $0.66 per share
• Price / Cash Flow: 2.58
• Book Value: $1.15 per share
• Price / Book: 1.49

Miscellaneous

• Outstanding Shares: 128,680,000
• Free Float: 104,484,000
• Market Cap: $220.04 million
• Optionable: Optionable
• Beta: 1.29